{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T11:48:19Z","timestamp":1790855299491,"version":"4.1.0"},"reference-count":29,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2004,5,15]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p> A phase I trial was conducted to determine the maximally tolerated dose (MTD) of concurrent weekly docetaxel and three-dimensional conformal radiation therapy (3-D CRT) in unfavorable localized adenocarcinoma of the prostate. <\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p> Patients with unfavorable localized adenocarcinoma of the prostate underwent daily 3-D CRT to a total dose of 70.2 Gy at 1.8 Gy\/fraction and concurrent docetaxel given once a week for 8 to 9 weeks. The initial weekly docetaxel dose level was 5 mg\/m<jats:sup>2<\/jats:sup> and the docetaxel doses were escalated as follows: 8, 12, 16, 20, and 25 mg\/m<jats:sup>2<\/jats:sup>. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p> Between January 2000 and August 2002, 22 men completed the chemoradiation therapy protocol. The dose-limiting toxicity was grade 3 diarrhea, which occurred in the first two patients treated at the 25 mg\/m<jats:sup>2<\/jats:sup> docetaxel dose level. The MTD of weekly docetaxel was determined to be 20 mg\/m<jats:sup>2<\/jats:sup>. The overall incidence of grade 2 diarrhea and grade 2 dysuria was 36% and 23%, respectively. Seven (32%) and 15 (68%) patients did not experience any diarrhea or dysuria, respectively. No neutropenia or thrombocytopenia was observed. One patient required intermittent urinary catherization 10 months postcompletion of therapy, which resolved without any surgical intervention. Seventeen patients remain in prostate-specific antigen remission. At a median follow-up interval of 8 months (range, 2 to 27 months), all patients are alive. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p> Concurrent weekly docetaxel in conjunction with 3-D CRT is well tolerated with acceptable toxicity. The MTD of weekly docetaxel was determined to be 20 mg\/m<jats:sup>2<\/jats:sup> with concurrent 3-D CRT. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2004.02.001","type":"journal-article","created":{"date-parts":[[2004,5,13]],"date-time":"2004-05-13T23:18:18Z","timestamp":1084490298000},"page":"1909-1915","source":"Crossref","is-referenced-by-count":52,"title":["Phase I Trial of Weekly Docetaxel With Concurrent Three-Dimensional Conformal Radiation Therapy in the Treatment of Unfavorable Localized Adenocarcinoma of the Prostate"],"prefix":"10.1200","volume":"22","author":[{"given":"Parvesh","family":"Kumar","sequence":"first","affiliation":[{"name":"From the Department of Radiation Oncology, University of Southern California Keck School of Medicine, Los Angeles, CA; Divisions of Medical Oncology and Urology and Departments of Surgery and Medicine, Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine & Dentistry of New Jersey, New Brunswick, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Perrotti","sequence":"additional","affiliation":[{"name":"From the Department of Radiation Oncology, University of Southern California Keck School of Medicine, Los Angeles, CA; Divisions of Medical Oncology and Urology and Departments of Surgery and Medicine, Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine & Dentistry of New Jersey, New Brunswick, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Weiss","sequence":"additional","affiliation":[{"name":"From the Department of Radiation Oncology, University of Southern California Keck School of Medicine, Los Angeles, CA; Divisions of Medical Oncology and Urology and Departments of Surgery and Medicine, Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine & Dentistry of New Jersey, New Brunswick, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Todd","sequence":"additional","affiliation":[{"name":"From the Department of Radiation Oncology, University of Southern California Keck School of Medicine, Los Angeles, CA; Divisions of Medical Oncology and Urology and Departments of Surgery and Medicine, Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine & Dentistry of New Jersey, New Brunswick, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Goodin","sequence":"additional","affiliation":[{"name":"From the Department of Radiation Oncology, University of Southern California Keck School of Medicine, Los Angeles, CA; Divisions of Medical Oncology and Urology and Departments of Surgery and Medicine, Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine & Dentistry of New Jersey, New Brunswick, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Cummings","sequence":"additional","affiliation":[{"name":"From the Department of Radiation Oncology, University of Southern California Keck School of Medicine, Los Angeles, CA; Divisions of Medical Oncology and Urology and Departments of Surgery and Medicine, Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine & Dentistry of New Jersey, New Brunswick, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"DiPaola","sequence":"additional","affiliation":[{"name":"From the Department of Radiation Oncology, University of Southern California Keck School of Medicine, Los Angeles, CA; Divisions of Medical Oncology and Urology and Departments of Surgery and Medicine, Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine & Dentistry of New Jersey, New Brunswick, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.54.1.8"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(02)02954-1"},{"key":"R3","doi-asserted-by":"crossref","unstructured":"Consensus statement: Guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys 37:1035,1997-1041,","DOI":"10.1016\/S0360-3016(97)00002-3"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(01)01579-6"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.99.160"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.11.023"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199707313370502"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198611133152014"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.1800840827"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1007\/BF01655808"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1021\/bi00062a003"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/83.4.288"},{"key":"R13","unstructured":"Hennequin C, Giocanti N, Favaudon V: Interaction of Ionizing Radiation with Paclitaxel (Taxol) and Docetaxel (Taxotere) in HeLa and SQ20B Cells. Cancer Res 56:1842,1996-1850,"},{"key":"R14","unstructured":"Milas L, Milas MM, Mason KA: Combination of taxanes with radiation: Preclinical studies. Semin Radiat Oncol 9:12,1999-26,"},{"key":"R15","unstructured":"Mason KA, Hunter NR, Milas M, et al: Docetaxel enhances tumor radioresponse in vivo. Clin Cancer Res 3:2431,1997-2438,"},{"key":"R16","unstructured":"Picus J, Shultz M: Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory cancer: Preliminary results. Semin Oncol 29:14,1999-18,  (suppl 17)"},{"key":"R17","unstructured":"Friedland D, Cohen J, Miller R, et al: A phase II trial of docetaxel in hormone-refractory prostate cancer: Correlation of antitumor effect to phosphorylation of bcl-2. Semin Oncol 26:19,1999-23,  (5 suppl 7)"},{"key":"R18","doi-asserted-by":"crossref","unstructured":"Kreis W, Budman DR, Fetten J, et al: Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma. Ann Oncol 10:33,1999-38,","DOI":"10.1023\/A:1008354600497"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.3.958"},{"key":"R20","doi-asserted-by":"crossref","unstructured":"Savarese DM, Halabi S, Hars V, et al: Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: A final report of CALGB 9780. Cancer and Leukemia Group B. J Clin Oncol 19:2509,2001-2516,","DOI":"10.1200\/JCO.2001.19.9.2509"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2001.26435"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1023\/A:1012258723075"},{"key":"R23","unstructured":"DiPaola R, Kumar P, Hait W, et al: State-of-the-art prostate cancer treatment and research. A report from The Cancer Institute of New Jersey. N J Med 98:23,2001-33,"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(01)01829-6"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.9.1936"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(00)01375-4"},{"key":"R27","unstructured":"Khil MS, Kim JH, Bricker LJ, et al: Tumor control of locally advanced prostate cancer following combined estramustine, vinblastine, and radiation therapy. Cancer J Sci Am 3:289,1997-296,"},{"key":"R28","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(97)10101-0"},{"key":"R29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.1.159"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2004.02.001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T20:48:19Z","timestamp":1653511699000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2004.02.001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,5,15]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2004,5,15]]}},"alternative-id":["10.1200\/JCO.2004.02.001"],"URL":"https:\/\/doi.org\/10.1200\/jco.2004.02.001","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,5,15]]}}}